Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
2008
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
2008
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
2008
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
2010
Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy
2011
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
2008
An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
1991
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.
1990
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
1992
Lapatinib
2007
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
2009
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
1991
The transcriptional repressor Snail promotes mammary tumor recurrence
2005
Hallmarks of Cancer: The Next Generation
2011 Standout
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
1993
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
1989
Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
1999
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
2012
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
2010
Neu-Protein Overexpression in Breast Cancer
1988
ErbB receptors and signaling pathways in cancer
2009
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
A view on drug resistance in cancer
2019 StandoutNature
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
1988
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
2005
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
2005
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
1998
Trastuzumab: triumphs and tribulations
2007
Genetic instabilities in human cancers
1998 StandoutNature
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
A genetic model for colorectal tumorigenesis
1990 Standout
Tumor-Promoting Phorbol Ester andras Oncogene Expression Inhibit the Glucocorticoid-Dependent Transcription from the Mouse Mammary Tumor Virus Long Terminal Repeat
1989
Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg®) in Acute Myeloid Leukemia
2002
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Evaluation of automated silver‐enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens
2009
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
2010 Nature
Breast cancer genomes — form and function
2010
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis
2002
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The p53 tumour suppressor gene
1991 StandoutNature
Increased expression of mutant forms of p53 oncogene in primary lung cancer
1990
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Molecular Determinants of Occult Metastatic Tumor Cells in Bone Marrow
2001
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
Immunohistochemical localization of c-erbB-2 in human breast carcinomas
1987
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
2005
Monoclonal antibodies as therapeutic agents for cancer
2004
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Localization of three genes expressed in retina on mouse Chromosome 11
1995
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Cancer immunotherapy comes of age
2011 StandoutNature
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Ligand-targeted therapeutics in anticancer therapy
2002
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Antibody–cytotoxic agent conjugates for cancer therapy
2005
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
2010
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
2014
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Arming antibodies: prospects and challenges for immunoconjugates
2005
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs
2011
c-erbB-2 expression in benign and malignant breast disease
1988
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
2003
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
2005
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Response : Amplification c- erb B-2 and Aggressive Human Breast Tumors?
1988 Science
Microarrays in primary breast cancer--lessons from chemotherapy studies.
2001
p53 Mutations in Human Cancers
1991 StandoutScience
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
A Water-Based Mechanism of Specificity and Resistance for Lapatinib with ErbB Family Kinases
2012
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis
1995 StandoutScience
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
2006
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
1990 StandoutScience
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION
1987
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
A first synthesis of 18F‐radiolabeled lapatinib: a potential tracer for positron emission tomographic imaging of ErbB1/ErbB2 tyrosine kinase activity
2011
Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
2003
The chromosomal distribution of mouse odorant receptor genes.
1996 StandoutNobel
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
1989 StandoutScience
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Works of Mark S. Berger being referenced
Preliminary report of an ascending dose study of gemtuzumab ozogamicin (mylotarg™, cma-676) in pediatric patients with acute myeloid leukemia
2000
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
2008
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
2006
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
1988
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
2001
Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse
2002
A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma
2003
Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse
2001
Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia
2002
Epidermal growth factor receptors in lung tumours
1987
The Gene for C10, a Member of the β-Chemokine Family, Is Located on Mouse Chromosome 11 and Contains a Novel Second Exon Not Found in Other Chemokines
1993
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
2005
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
2001
Expression of the c‐erbB‐2 protein in normal and transformed cells
1987
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
2001